Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/26
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsBusiness Wire • 08/06/26
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should KnowZacks Investment Research • 05/28/26
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/26
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsBusiness Wire • 05/07/26
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%Zacks Investment Research • 05/07/26
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash ValueSeeking Alpha • 05/04/26
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014Business Wire • 04/16/26
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone PaymentBusiness Wire • 04/01/26
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsBusiness Wire • 02/26/26
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?Zacks Investment Research • 02/03/26
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical OfficerBusiness Wire • 01/26/26
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drugReuters • 01/22/26
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid TumorsBusiness Wire • 01/22/26